R&D,Bioprocess,Weekly Roundups

Weekly News Round-up – 31/1/20

3 weeks ago By admin
  • Share on

  • Facebook
  • Linkedin

With the Chinese Coronavirus dominating the news this week, headlines were a diverse affair: Novartis has backed out of a generic program copying Advair, with the company citing that they could no longer see a way to launch in the next few years. In other nes, an AI-developed drug has reached human trials for the first time ever in what promises to be an interesting first in drug discovery, and almost 50 drugs were found to have additional applicability in cancer, thanks to a large-scale study by MIT and Harvard.

NOVARTIS BACKS AWAY FROM $442 MILLION ADVAIR COPY - Novartis is discontinuing its Advair copy after the FDA rejected it in 2018 and new data showed there was no longer a "pathway to launch in the next 18 months". The reversal is costing Novartis $442 million in write-offs of development work and other investments.

AI-DESIGNED DRUG TO ENTER HUMAN TRIALS FOR FIRST TIME - DSP-1181, a drug to combat OCD, has been discovered by a joint effort between Sumitomo Dainippon Pharma and Exscientia's AI algorithms. DSP-1181 is now set to enter human trials in a major medicinal milestone, the first time an AI-discovered drug has done so. Exscientia's AI analysed patient genetic data to find molecules useful to new medicine in only twelve months, while most development cycles take more than five years.

NEARLY 50 NON-ONCOLOGY DRUGS FOUND TO KILL CANCER CELLS - Research by the MIT Broad Institute and Harvard has discovered that, of 4,518 drug compounds, almost 50 work well when tested on 578 cancer cell lines, and have unforeseen utility against cancer. The drugs currently target, among other things, inflammation, alcoholism, and arthritis in dogs.

In other news: 

Manufacturing
The most and least expensive countries to run a pharma plant

That’s all for now. See you next week!

Joshua Neil, Editor
Proventa International

More news

How to Select a CMO in Biomanufacturing

Experts often regard biomanufacturing efficiency as the most important part of global bioprocessing. But efficiency can be almost impossible as companies juggle hundreds of priorities across dozens of areas in the pipeline. Best practice can easily be subsumed by a...

1 day ago
R&D,Bioprocess,Weekly Roundups

How to Select a CMO in Biomanufacturing

Experts often regard biomanufacturing efficiency as the most important part of global bioprocessing. But efficiency can be almost impossible as companies juggle hundreds of priorities across dozens of areas in the pipeline. Best practice can easily be subsumed by a...

1 day ago

Weekly News Round-up – 14/2/20

The U.S. Institute for Clinical and Economic Review’s (ICER’s) methods could see legal challenges in the near future, a think tank has warned, due to discrimination against disabled individuals. In other news, Novartis’ rare lung cancer drug capmatinib will be...

6 days ago
R&D,Bioprocess,Weekly Roundups

Weekly News Round-up – 14/2/20

The U.S. Institute for Clinical and Economic Review’s (ICER’s) methods could see legal challenges in the near future, a think tank has warned, due to discrimination against disabled individuals. In other news, Novartis’ rare lung cancer drug capmatinib will be...

6 days ago

The Changing Role of the Blockbuster Drug

There are few pharmaceutical companies not seeking the next big "blockbuster", a market drug earning revenue over $1 billion. These big-name products, which include Keytruda and Lipitor, are well-marketed and broadly-effective, often across several illnesses. For years scientists have worked...

1 week ago
R&D,Bioprocess,Weekly Roundups

The Changing Role of the Blockbuster Drug

There are few pharmaceutical companies not seeking the next big "blockbuster", a market drug earning revenue over $1 billion. These big-name products, which include Keytruda and Lipitor, are well-marketed and broadly-effective, often across several illnesses. For years scientists have worked...

1 week ago
Working With us

Interested?
Reserve your space